|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-3-9
|
|
pubmed:abstractText |
The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis E virus (HEV). The safety and immunogenicity of the vaccine for humans was assessed in a randomized controlled phase II clinical trial. The study was conducted in an endemic area of southern China and consisted of a dose scheduling, involving 457 adults and a dose escalation component involving 155 high school students. The results showed that the vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
pubmed-author:DunnH KHK,
pubmed-author:GeSheng-XiangSX,
pubmed-author:LiRong-ChengRC,
pubmed-author:LiYan-PingYP,
pubmed-author:LiYi-MinYM,
pubmed-author:LiuChong-BoCB,
pubmed-author:NgMun-HonMH,
pubmed-author:NongYiY,
pubmed-author:PanBai-BinBB,
pubmed-author:ShihJames Wai-KuoJW,
pubmed-author:XiaNing-ShaoNS,
pubmed-author:XiongJun-HuiJH,
pubmed-author:ZhangJunJ,
pubmed-author:ZhengYing-JieYJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1869-74
|
|
pubmed:meshHeading |
pubmed-meshheading:19168109-Adolescent,
pubmed-meshheading:19168109-Adult,
pubmed-meshheading:19168109-Antibodies, Viral,
pubmed-meshheading:19168109-China,
pubmed-meshheading:19168109-Dose-Response Relationship, Immunologic,
pubmed-meshheading:19168109-Endemic Diseases,
pubmed-meshheading:19168109-Female,
pubmed-meshheading:19168109-Follow-Up Studies,
pubmed-meshheading:19168109-Hepatitis E,
pubmed-meshheading:19168109-Hepatitis E virus,
pubmed-meshheading:19168109-Humans,
pubmed-meshheading:19168109-Immunoglobulin G,
pubmed-meshheading:19168109-Male,
pubmed-meshheading:19168109-Middle Aged,
pubmed-meshheading:19168109-Reference Standards,
pubmed-meshheading:19168109-Treatment Outcome,
pubmed-meshheading:19168109-Vaccines, Synthetic,
pubmed-meshheading:19168109-Viral Vaccines,
pubmed-meshheading:19168109-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.
|
|
pubmed:affiliation |
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361005, China.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
